Vertex Pharmaceuticals is down 1% after the company said it expected FY16 KALYDECO sales of $703 million and $979 million for ORKAMBI. Total cystic fibrosis (CF) product revenues are seen rising to $1.68 billion compared to $983 million in 2015.
Q4 ORKAMBI sales are seen about $276 million and KALYDECO sales about $177 million. Total Q4 CF product revenues are expected about $453 million. 2016 ORKAMBI revenues do not include any revenues from France, where approximately 1,000 of the 1,500 eligible patients have initiated therapy as of the end of 2016.
For FY17, it sees KALYDECO product revenues between $690 million to $710 million and ORKAMBI product revenues between $1.1 billion to $1.3 billion.